Neurovision Pharma

Neurovision Pharma is an intellectual property holding company co-founded by two neurology experts and a patent attorney specializing in the drafting, prosecution, and defense of pharmaceutical patents. The company owns patents for ASOs that exclusively target the TGFBRII receptor in over 35 countries worldwide. It includes six pairs of ASO candidates covering all available targeting sites of TGFBRII and addresses approximately 50 diseases, including fibrotic diseases, dementia, Alzheimer's disease, Parkinson's syndrome, ALS, and aging of the central nervous system.